149 related articles for article (PubMed ID: 33847940)
1. Detection of C3 Nephritic Factor by Hemolytic Assay.
Chabannes M; Frémeaux-Bacchi V; Chauvet S
Methods Mol Biol; 2021; 2227():147-158. PubMed ID: 33847940
[TBL] [Abstract][Full Text] [Related]
2. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
3. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
4. Sheep Erythrocyte Preparation for Hemolytic Tests Exploring Complement Functional Activities.
Chabannes M; Bordereau P; Martins PV; Dragon-Durey MA
Methods Mol Biol; 2021; 2227():61-67. PubMed ID: 33847931
[TBL] [Abstract][Full Text] [Related]
5. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
6. A hemolytic method for the measurement of nephritic factor.
West CD
J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
[TBL] [Abstract][Full Text] [Related]
7. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
8. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes.
Rother U
J Immunol Methods; 1982; 51(1):101-7. PubMed ID: 6921216
[TBL] [Abstract][Full Text] [Related]
9. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
11. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
Mold C; Medof ME
Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
[TBL] [Abstract][Full Text] [Related]
12. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
13. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
[TBL] [Abstract][Full Text] [Related]
14. A C3 convertase assay for nephritic factor functional activity.
Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
[TBL] [Abstract][Full Text] [Related]
15. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
Daha MR; van Es LA
J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
17. Analysis of C3 Nephritic Factors by ELISA.
Skattum L
Methods Mol Biol; 2019; 1901():177-182. PubMed ID: 30539576
[TBL] [Abstract][Full Text] [Related]
18. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
19. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
20. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
Ohi H; Watanabe S; Fujita T; Yasugi T
Clin Exp Immunol; 1992 Sep; 89(3):479-84. PubMed ID: 1516262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
